Form 4: Forte Biosciences CFO Receives Equity Awards

Forte Biosciences' Chief Financial Officer, Antony A. Riley, was granted 150,000 equity awards, including stock options and restricted stock units, vesting over four years.

Summary

• Antony A. Riley, Chief Financial Officer of Forte Biosciences, Inc. (FBRX), received equity awards on January 12, 2026.
• The awards include 90,000 stock options with an exercise price of $29.66 per share.
• The stock options vest monthly over four years, with full vesting on the four-year anniversary of the January 1, 2026 Vesting Commencement Date.
• Additionally, 60,000 Restricted Stock Units (RSUs) were granted, each representing a contingent right to receive one share of common stock.
• The RSUs vest annually over four years, with full vesting on the four-year anniversary of the January 1, 2026 Vesting Commencement Date.
• Both awards are subject to Mr. Riley continuing to be a Service Provider as defined in the 2021 Equity Incentive Plan.

Sentiment

Score: 6

Explanation: The grant of equity awards to a key executive is generally a positive signal, aligning management's interests with shareholders and promoting retention. However, it's a routine disclosure and not indicative of immediate operational or financial performance changes.

Positives

• The grant of 150,000 equity awards (90,000 stock options and 60,000 RSUs) to the Chief Financial Officer aligns management's interests with those of shareholders.
• The multi-year vesting schedule (four years) promotes long-term retention of a key executive.

Negatives

• The future exercise of stock options and vesting of RSUs will result in a minor dilution of existing shareholder equity.

Risks

• The vesting of both stock options and Restricted Stock Units is contingent upon Antony A. Riley continuing to be a "Service Provider" through each applicable vesting date.

Future Outlook

The equity awards, with their multi-year vesting schedules, indicate a long-term commitment from the Chief Financial Officer to Forte Biosciences, Inc. and are designed to incentivize continued service and performance over the next four years.

Industry Context

The granting of stock options and restricted stock units to key executives is a standard practice in the biotechnology and pharmaceutical industries, aiming to attract, retain, and motivate talent by aligning their financial incentives with the long-term performance of the company and shareholder value creation.

Comparison to Industry Standards

• The use of a combination of stock options and Restricted Stock Units (RSUs) for executive compensation is a common practice across the biotechnology sector, similar to compensation structures seen at companies like Moderna, BioNTech, or Regeneron.
• A four-year vesting schedule for equity awards is typical for executive compensation plans in the U.S. market, providing a balance between retention and performance incentives.
• The specific number of shares granted (150,000 total) would need to be benchmarked against peer companies of similar market capitalization and stage of development to assess if it is within industry norms, but the structure itself is standard.

Corporate Governance

Stakeholder Impact

• Shareholders: Interests are potentially better aligned with the CFO due to the equity awards. There will be minor future dilution upon vesting and exercise.
• Employees: The equity grant to a senior executive may signal stability and a commitment to long-term incentives within the company.

Next Steps

• Antony A. Riley must continue to serve as a "Service Provider" to Forte Biosciences, Inc. to ensure the vesting of his stock options and Restricted Stock Units.

Key Dates

Keywords

Forte Biosciences, FBRX, SEC Form 4, Equity Grant, Stock Options, Restricted Stock Units, CFO Compensation, Insider Transaction, Executive Compensation